A study on the effect of hemodialysis on the blood concentration of rifampicin

doi:10.19871/j.cnki.xfcrbzz.2023.02.012

Abstract

Abstract: Objective By analyzing the characteristics of rifampicin concentration in hemodialysis patients, to understand whether hemodialysis treatment affects rifampicin concentration, and to provide a basis for the scientific anti-tuberculosis treatment plan for patients receiving long-term hemodialysis. Method Analyzed 149 patients hospitalized with pulmonary tuberculosis in the Fourth People's Hospital of Nanning City from July 2021 to July 2022, and divided the patients into hemodialysis group (43 cases) and non-hemodialysis group (106 cases). By using high performance liquid chromatography analysis to measure the changes of rifampicin blood concentration on post rifampin treatment on days 8 at 2 hours, 4 hours and 6hours. Result There was no statistically significant difference in the blood concentration of rifampicin between hemodialysis group and non-hemodialysis group (P>0.05). Higher rifampicin blood levels accompanied by a sever hepatic dysfunction and exacerbate liver injury after anti-tuberculosis treatmen (P<0.05). The ratio of delayed blood concentration and oral patients is overrepresented in the haemodialysis group. Conclusion There was no significant effect of haemodialysis on the blood concentration of rifampicin, and no top-up dose was needed; the ratio of rifampicin blood level in the haemodialysis group was higher than that in the non-haemodialysis group, which was considered to be affected by the orally. Individualized anti-tuberculosis treatment basing on the blood concentration of rifampicin at 2h, 4h and 6h after the use of drugs can ensure the therapeutic effects.

Key words: Hemodialysis, Rifampicin, Blood drug concentration, Pulmonary tuberculosis

CLC Number:

R452
R459.5

Su Chunxiong, Wei Lijuan, Zhou Jia, Huang Aixian, Deng Wenhai, Qin Hongfa, Qin Guoqing, Xu Qiuna, Zou Jun. A study on the effect of hemodialysis on the blood concentration of rifampicin[J]. Electronic Journal of Emerging Infectious Diseases, 2023, 8(2): 58-62.

References

[1] WORLD HEALTH ORGANIZATION.Global tuberculosis report 2022[EB/OL].https://www.who.int/teams/globaltuberculosis-programme/tb-reports/global-tuberculosisreport-2022.
[2] VAN DEN ELSEN SHJ, AKKERMAN OW, WESSELS M, et al. Dose optimisation of first-line tuberculosis drugs using therapeutic drug monitoring in saliva: feasible for rifampicin, not for isoniazid[J]. Eur Respir J, 2020, 56(4):2000803.
[3] PRAHL JB, JOHANSEN IS, FRIMODT-M LLER N, el al. Clinical significance of 2-hour plasma concentrations of first-line tuberculosis drugs[D].lnterscience Conference on Anti-microbial Agents and Chemotherapy, Denver, CO2013.
[4] SIN JH, ELSHABOURY RH, HURTADO RM, et al.Therapeutic drug monitoring of antitubercular agents for disseminated Mycobacterium tuberculosis during intermittent haemodialysis and continuous venovenous haemofiltration[J]. Clin Pharm Ther, 2018, 2(43):291-295.
[5] CHAWLA PK, UDWADIA ZF, SOMAN R, et al.Importance of Therapeutic Drug Monitoring of Rifampicin[J]. J Assoc Physicians India, 2016, 8(64):68-72.
[6] 赵凯, 温立鸿. 服用利福平后2h和6h血药浓度作为药峰浓度指导临床用药的可行性研究[J]. 中国合理用药探索, 2021,18(6):54-57.
[7] 张相林. 治疗药物检测临床应用手册[M]. 北京:人民卫生出版社, 2020:40-50.
[8] 周俊, 吕小会, 郑修齐, 等. 三种抗结核药物血药浓度调控成功率的比较分析[J]. 中国防痨杂志, 2018, 40(9):969-972.
[9] MALONE RS, FISH DN, SPIEGEL DM, et al.The effect of hemodi- alysis on isoniazid, rifampin, pyrazinamide, and ethambutol[J]. Am J Respir Crit Care Med, 1999, 159(5 Pt 1):1580-1584.
[10] WHO Guidelines Approved by the Guidelines Review Committee. T reatment of Tuberculosis: Guidelines. Geneva: World Health Organization[R]. World Health Organization, Copyright 2010.
[11] ERWIN ER, ADDISON AP, JOHN SF, et al.Pharmacokinetics of isoniazid: The good, the bad, and the alternatives[J].Tuberculosis, 2019, (116):66-70.
[12] PELOQUIN CA, JARESKO GS, YONG CL, et al.Population pharmacokinetic modeling of isoniazid, rifampin, and pyrazinamide[J]. Antimicrob Agents Chemother, 1997 ,41(12): 2670-2679.
[13] 中华医学会结核病学分会.抗结核药物性肝损伤诊治指南(2019年版)[J]. 中华结核和呼吸杂志, 2019, 42(5):343-356.
[14] ZHAO G, CHEN M, SUN L, et al.Analysis of influencing factors on the plasma concentration of first-line anti-tuberculosis drugs-a single-center retrospective cohort study[J]. Annals of translational medicine, 2022, 8(10):461-461.
[15] WOO J, CHEUNG W, CHAN R, et al.In vitro protein binding characteristics of isoniazid, rifampicin, and pyrazinamide to whole plasma, albumin, and alpha-1-acid glycoprotein[J]. Clin Biochem, 1996, 29(2):175-177.
[16] 张培泽, 郑俊峰, 曹炜鹏, 等. 服用利福平后两个时间段监测血药浓度的研究[J]. 中国防痨杂志, 2020, 42(5):493-497.
[17] 魏香兰, 方如塘, 师延峰, 等. 抗结核药物的血药浓度监测结果分析[J]. 中国医院药学杂志,2015, 21(35):1918-1921.
[18] SAKTIAWATI AMI, HARKEMA M, SETYAWAN A, et al.Optimal Sampling Strategies for Therapeutic Drug Monitoring of First-Line Tuberculosis Drugs in Patients with Tuberculosis.[J].Clin Pharmacokinet,2019,11(58):1445-1454.
[19] 卢春容, 谭卫国, 卓志鹏, 等. 年深圳市结核病细菌耐异烟肼、利福平流行趋势分析[J/CD]. 新发传染病电子杂志, 2017, 2(1):10-13.
[20] WILKKINS JJ, SAVIC RM, KARLSSON MO, et al.Population pharmacokinetics of rifampin in pulmonary tuberculosis patients, including a semimechanistic model to describe variable absorption[J]. Antimicrob Agents Chemother, 2008, 52(6):2138-2148.
[21] CURIE AHN, KOOK-HWAN OH,KIWON KIM, et al.Effect of peritoneal dialysis on plasma and peritoneal fluid concentrations of isoniazid, pyrazinamide, and rifampin[J]. Perit Dial Int, 2003, 23(4):362-367.